Keith Alexander
CFO
Replay available
ExpreS2ion Biotech Holding AB (publ) (EXPRS2) Q3 2025 Earnings Call
ExpreS2ion Biotech Holding AB (publ) (STO: EXPRS2) Q3 2025 earnings conference call, held 2025-11-13. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Ben Fransen
CEO
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Expres2ion Biotech Holding Ab.
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:03.600 Welcome to today's event where we have the pleasure to present expression biotechnology. 00:00:03.600 -- 00:00:07.629 To help us through today's presentation, we are joined by CEO Ben Fransen and CFO Keith 00:00:07.629 -- 00:00:12.621 Alexander. The topic, of course, you could see a report this morning, but I think more 00:00:12.621 -- 00:00:18.014 abroad, a very large news flow coming in the course on a lot of other 00:00:18.014 -- 00:00:22.901 than the financials as always ask questions in the box down below i'm speaking fast we 00:00:22.901 -- 00:00:28.228 have a firm deadline at 11 30 we will try and catch as many questions as possible 00:00:28.228 -- 00:00:33.316 but uh you will have joined a lot of events presentations here in in the coming days 00:00:33.316 -- 00:00:38.884 so i think people will have a good way a good possibility to ask questions 00:00:38.884 -- 00:00:43.290 later on but for now i have the call over to you bent 00:00:43.290 -- 00:00:44.868 thank you very much michael 00:00:44.868 -- 00:00:49.637 Good morning, everybody, and welcome to Expressions' third quarter webcast. 00:00:49.637 -- 00:00:54.546 I'm Ben Fransen, CEO of Expressions Biotechnologies, and with me today is our CFO, Keith 00:00:54.546 -- 00:00:55.989 Alexander. 00:00:55.989 -- 00:01:00.317 We'll take you through our progress this quarter, how we are advancing our HER2 breast 00:01:00.317 -- 00:01:05.347 cancer immunotherapy, expanding on global vaccine partnerships, and keeping track 00:01:05.347 -- 00:01:08.269 on our financial position. 00:01:08.543 -- 00:01:14.110 We'll start with strategy and pipeline updates, focusing on clinical progress, collaborations 00:01:14.110 -- 00:01:19.016 and upcoming catalysts. And then Kies will walk you throu...